All patients
Matched-pair analysis
Figure. Overall survival in lower IPSS risk MDS from red blood cell transfusion dependence by receipt of iron chelation therapy a) in all patients; b) in patients matched 1:1 for age (≤50, 51-60, 61-65, 66-70, 71-75, 76-80, and >80 years), IPSS-R score (very low + low, intermediate, and high + very high), number of RBC units/month transfused (0, >0-≤2, >2-≤4, >4-≤6, & >6), and time from MDS dx until RBC transfusion dependence (0, >0-<6, >6-36, >36 months).